Prevalence of JAK2 V617F mutation in BCR::ABL negative classical myeloproliferative neoplasm along with a comparison of two mutant allele burden detection techniques
DOI:
https://doi.org/10.21276/bb6g4y37Keywords:
BCR::ABL1 negative classic MPN, PV, ET, PMF, JAK2 V617F mutation, ARMS-PCRAbstract
Background: JAK2V617F mutation is the main driver mutation identified in BCR::ABL1 negative classical myeloproliferative neoplasm (MPNs), which includes Essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF). The aim of this study was to evaluate the prevalence of JAK2V617F mutation in these MPNs and to compare the measurement of mutant allele burden using commercial q-PCR kit and ARMS-PCR followed by fragment analysis. Methods: JAK2V617F mutation status using ARMS PCR was analysed for all consecutive cases of BCR::ABL1 negative MPNs over a period of 6.5 years. Eighteen randomly selected JAK2V617F mutated samples, across all the three disease groups, were taken for JAK2V617F quantitation using Ipsogen JAK2 RGQ-PCR Kit and ARMS-PCR followed by fragment analysis. Prevalence of mutation, allele burden among different disease groups and the two detection methods were compared. Results: Out of 378 cases studied, JAK2V61F mutation was noted in 113/124 (91.1%) cases of PV, 92/133 (69.2%) cases of PMF, and 74/121 (61.1%) cases of ET. The median allele burden in ET, PV and PMF were 37.8%, 77.3% and 88.9%, respectively. There was a good concordance rate between the two methods of JAK2V617F quantitation (r = 0.851). The cost per test with ARMS-PCR followed by fragment analysis was lower as compared RGQ PCR (INR 2400 vs INR 3600). Conclusion: JAK2V617F mutation is seen in majority of BCR::ABL1 negative classic MPNs. In-house validated method for quantitation using ARMS-PCR followed by fragment analysis is a reliable and cheaper alternative
Downloads

Published
Issue
Section
License
Copyright (c) 2024 International Archives of BioMedical and Clinical Research

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors are required to sign and submit the completed “Copyright transfer Form” upon acceptance of publication of the paper. This is determined by a publishing agreement between the author and International Archives of Biomedical and Clinical Research. These rights might include the right to publish, communicate and distribute online. Author(s) retain the copyright of their work. International Archives of Biomedical and Clinical Research supports the need for authors to share, disseminate and maximize the impact of their research.